Cancer Therapy News and Research

RSS

Diffusion MRI gives early indication if brain cancer therapy is effective

A special type of MRI scan that measures the flow of water molecules through the brain can help doctors determine early in the course of brain cancer regimen if a patient's tumor will shrink, a new study shows.

28 Mar 2005

Smart nanocarrier technology will cancer treatment

A ‘smart’ nanocarrier technology developed by a team of researchers at the Institute of Bioengineering and Nanotechnology (IBN) is set to vastly improve the way cancer patients are treated.

22 Mar 2005

Most cancer patients can be very hopeful for a good outcome and a continued ability to work

Only one of five cancer survivors surveyed in a Penn State study were disabled or out of work four years after treatment, but a minority suffered lasting effects that prevented them from working.

22 Mar 2005

pSivida intensifies research activities

Following extremely encouraging Phase IIa clinical trial results showing successful tumor regression and safety in man, nanotechnology pioneer pSivida Limited is intensifying development of its fully patented invention of nanostructured bioactive, biodegradable and biocompatible silicon (BioSilicon™) for multiple potential healthcare applications.

21 Mar 2005

Cancer survival comes at its own price

Patients who hear the dreaded words "you have cancer" invariably look forward to the day the doctor tells them "you're cured." But University of Florida researchers say survival often comes at its own price -- the mind may need mending even after the body heals.

16 Mar 2005

Drug combo gives lung cancer patients longer life

Preliminary results from a large randomized clinical trial, sponsored by the National Cancer Institute (NCI), by a network of researchers led by the Eastern Cooperative Oncology Group. Genentech, Inc., have shown that patients with previously untreated advanced non-squamous non-small cell lung cancer who received bevacizumab (Avastin) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Bevacizumab (Avastin) in combination with standard chemotherapy helps advanced lung cancer sufferers

Preliminary results from a large, randomized clinical trial for patients with previously untreated advanced non-squamous, non-small cell lung cancer show that those patients who received bevacizumab (AvastinTM) in combination with standard chemotherapy lived longer than patients who received the same chemotherapy without bevacizumab.

15 Mar 2005

Novel Australian anti-cancer therapy has begun safety testing in human subjects

An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.

15 Mar 2005

Good results in new lung cancer treatment

Interim analysis of a Phase III study of Avastin (bevacizumab) with paclitaxel and carboplatin chemotherapies in first-line non-squamous, non-small cell lung cancer (NSCLC) met its primary goal of improving overall survival, or a reduction in the risk of death, compared to chemotherapy alone.

15 Mar 2005

New cancer drug looks promising

Dr. E. Premkumar Reddy from Temple University School of Medicine and colleagues, in a study examining the effects of Plk1 inhibitor ON01910 on tumor growth in several animal models have found that a small molecule inhibitor of polo-like kinase1 (Plk1) could lead to a new avenue for targeted cancer therapy.

14 Mar 2005

Molecule called DJ-1 is likely to be involved in the generation of human tumors

Scientists have discovered that a molecule called DJ-1 is likely to be involved in the generation of human tumors through negative regulation of the well-known tumor suppressor, PTEN. The research, published in the March issue of Cancer Cell, has important implications for determining the prognosis of some human cancers, and may prove to be a suitable target for cancer therapy.

14 Mar 2005

Cryoablation effective, safe, durable treatment for prostate cancer

Endocare today announced that 10-year follow-up data from a retrospective study demonstrated that cryoablation as a treatment for prostate cancer has a biochemical disease free survival rate of 77 percent.

14 Mar 2005

Telomerase finding has major implications for cancer

UCLA biochemists have determined the three-dimensional structure of a major domain of telomerase, the enzyme that helps maintain telomeres - small pieces of DNA on the ends of chromosomes that act as protective caps - allowing DNA ends to be copied completely when cells are replicated.

9 Mar 2005

New chemotherapy gives hope to brain tumour patients

A large international study conducted by the European Organisation for Research and Treatment of Cancer (EORTC) in collaboration with the National Cancer Institute of Canada (NCIC) Clinical Trials Group demonstrated that the addition of a novel chemotherapy agent, Temozolomide (brand name: Temodal®) to radiation therapy increases survival in patients suffering from glioblastoma, a very aggressive form of a brain tumour.

9 Mar 2005

Thalidomide may have a new lease of life as a cancer treatment

The drug thalidomide may have a new lease of life as a cancer treatment. A small study published in Gut suggests that it slows down the weight loss and wasting associated with advanced disease in patients with pancreatic cancer.

7 Mar 2005

ViroLogic and AstraZeneca to conduct Iressa biomarker study

ViroLogic announced today that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, AstraZeneca's selective epidermal growth factor receptor kinase inhibitor.

7 Mar 2005

Nuclear reactor as a cancer cure

Despite the millions of dollars that have been invested into research to improve methods of treatments for various types of cancer, oncological diseases continue to have a high mortality rate, remaining one of the main causes of death globally. Traditional cancer treatment methods, such as chemotherapy, immunotherapy, and radiotherapy are effective in approximately only half of all patients.

3 Mar 2005

Celebrex provides a two pronged attack against prostate cancer

Celecoxib, a selective COX-2 inhibitor with promising anti-cancer properties, has now been found to attack prostate cancer cells in a second way that differs from Vioxx (rofecoxib), another anti-inflammatory drug that also inhibits COX-2.

1 Mar 2005

Importance of Fbw7 as an emerging tumor suppressor

The DNA tumor virus simian virus 40 produces the Large T antigen which inactivates two of the cell's most important cancer-preventing proteins, p53 and pRb.

27 Feb 2005

Protein called CK2 plays a deadly role in colorectal carcinoma

A protein called CK2 plays a deadly role in colorectal carcinoma by blocking the ability of these tumors to activate a natural self-destruct mechanism that would clear this cancer from the body. This finding, by researchers at St. Jude Children's Research Hospital, is currently published in the online edition of Oncogene.

24 Feb 2005